40 results about "Macroglobulins" patented technology

The present invention provides a method of diagnosing the presence or severity of liver fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of liver fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1.

The present invention provides a method of improving or prolonging a subject's immune response to a vaccine composition comprising heat shock protein (HSP)-peptide complexes or alpha-2-macroglobulin (alpha2M)-peptide complexes (hereinafter "HSP / alpha2M vaccine composition"). The HSP-peptide complexes or alpha2M-peptide complexes of the vaccine composition comprise HSP(s) or alpha2M complexed to a component against which an immune response is desired to be induced. In particular the invention is directed to methods of improving or prolonging a subject's immune response comprising administering an HSP / alpha2M vaccine composition in conjunction with a preparation comprising HSP or alpha2M, alone or complexed to a peptide that is not the component against which an immune response is desired to be induced (hereinafter "HSP / alpha2M preparation"), i.e., the HSP / alpha2M preparation does not display the immunogenicity of the component. In particular, HSP / alpha2M vaccine compositions are administered in conjunction with HSP / alpha2M preparation to improve or prolong the immune response of a subject against an infectious disease or cancer.

A method for removing a serum albumin from a mixture of other compounds by contacting said mixture with a ligand a) having affinity for and enabling selective binding of the serum albumin and b) being attached to a base matrix insoluble in the aqueous media used or being possible to attach to such a matrix after having become bound to the serum albumin, characterized in that said ligand is derived from an albumin binding bacterial cell surface receptor and that the ligand lacks the IgG-binding and / or alpha2-macroglobulin-binding ability found in native forms of these type of bacterial receptors. An albumin-binding ligand derived from a cell surface bacterial receptor and attached covalently to a carrier matrix, characterized in that the ligand is monovalent with respect to ability to bind a serum albumin. A method for removal of serum albumin from a sample that is to be assayed for non-serum albumin components. The characteristic feature is to subject the sample to affinity adsorption by an albumin-binding ligand derived from an albumin-binding receptor.

The present invention is related to a method for blocking the infection of cells by dengue virus, based on interfering the direct interaction of the viral envelope protein with a cellular receptor or its indirect interaction with said cellular receptor through a carrier protein, as well as related uses; wherein said cellular receptor is the alpha-2 macroglobulin receptor, also known as the low density receptor-related protein or as CD91, and said carrier protein is human alpha-2 macroglobulin.

The present invention relates to complexes of alpha (2) macroglobulin associated with antigenic molecules for use in immunotherapy. The invention relates to methods for using such compositions in the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

The present invention provides a method of diagnosing the presence or severity of tissue fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of tissue fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1.

This invention provides bioactive conjugates. The bioactive conjugates include: (1) a cell recognition moiety that binds to α2 macroglobulin receptor α2-MR and (2) a bioactive moiety which: (a) has a biological activity, (b) does not function solely as an immunogen to invoke an immune response and (c) does not have ADP ribosylating activity. The bioactive conjugates of this invention are useful in methods of transporting the bioactive moiety across a polar epithelial membrane. Thus, this invention provides methods for parenteral administration of proteins without injection.

The present invention relates to the use of alpha (2) macroglobulin ("alpha2M") receptor as a heat shock protein receptor, cells that express the alpha2M receptor bound to an HSP, and antibodies and other molecules that bind the alpha2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that interact with the alpha2M receptor, and modulate the interaction of the alpha2M receptor with its ligand, such as HSPs, and methods for using compositions comprising alpha2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.

The invention concerns a method for the detection of the presence and / or the severity of a liver disease in a patient comprising measuring in an isolated sample TIMP-1 (Tissue Inhibitor of Metalloproteinase I), A2M (a-2-macroglobulin), PLT (number of blood plateletes, PI (prothrombin index), optionally at least one additional parameter selected from the group consisting of urea and GGT (γ-glutamyltranspeptidase) and optionally measuring at least one additional biochemical or clinical parameter and diagnosing the presence and / or severity of a liver disease based on the presence or measured levels of these parameters. The method can be used for monitoring therapeutic treatment of liver fibrosis and staging of liver fibrosis.

A high-sensitivity human urine alpha2-macroglobulin detection kit belongs to the field of detection kits and comprises a reagent R1, a reagent R2, a calibration product and a quality control product,wherein the reagent R1 contains a buffer solution, salt, an accelerant, an anti-interference agent and a preservative; the reagent R2 contains a buffer solution, antiserum, a stabilizer and a preservative; the calibration product contains a buffer solution, serum, a stabilizer and a preservative; the quality control product contains a buffer solution, serum, a stabilizer and a preservative; wherein the antiserum is anti-human alpha2-MG antiserum. The serum is human serum or animal serum. According to the invention, the sensitivity of the kit is improved by using a buffer solution compounding method; the content of alpha 2-macroglobulin in human urine is detected through immunoturbidimetry, a urine sample is directly tested on a machine without manual treatment, an anti-interference agent is added into the reagent, the sensitivity of the reagent is effectively improved, so that the test accuracy of the urine sample is improved, and the kit is suitable for various full-automatic biochemical analyzers and has wider universality.

The invention relates to a hybridomas cell strain secreting anti-human macroglobulin monoclonal antibody and a preparation method thereof. The preparation method comprises using a conjugate obtaining by performing coupling on bovine serum albumin (BSA) and human macroglobulin as an antigen for immunizing Balb / c mouse, getting spleen cell of the mouse and performing cell fusion with SP2 / 0 myeloma cell, performing selective culture by using HAT medium, performing multiple cloning by using a limiting dilution process, and finally screening and obtaining the hybridomas cell strain stably secreting anti-human macroglobulin monoclonal antibody. The prepared hybridomas cell strain is preserved in China Center for Type Culture Collection with the preservation number of CCTCC C2015190.

The present invention relates to the use of alpha (2) macroglobulin (“α2M”) receptor as a heat shock protein receptor, cells that express the α2M receptor bound to an HSP, and antibodies and other molecules that bind the α2M receptor-HSP complex. The invention also relates to screening assays to identify compounds that modulate the interaction of an HSP with the α2M receptor, and methods for using compositions comprising α2M-receptor sequences for the diagnosis and treatment of immune disorders, proliferative disorders, and infectious diseases.

Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, -2-macroglobulin, prothrombin, immunoglobulin A and complement factor H.

The present invention discloses a method for separating and purifying α2-macroglobulin from Cohn Fraction IV precipitation, in which Cohn Fraction IV precipitation is treated by ammonium sulfate precipitation, zinc ion affinity chromatography, gel filtration, and ultrafiltration and concentration sequentially and thereby α2-macroglobulin is obtained finally. With the method provided in the present invention, purified α2-macroglobulin plasma protein that has a clinical application value is obtained, the Cohn Fraction IV precipitation is changed from a discarded material into a valuable material, and plasma is utilized comprehensively. In addition, the method is easy and simple to use, easy to scale up, and suitable for separation and purification of α2-macroglobulin at a large scale.

The invention discloses an AD biomarker and a detection method thereof. The AD biomarker comprises at least one of Protein-glutamine gamma-glutamyltransferase E, Protein S100-A12, Alph-2-macroglobulin-like protein 1, Polymeric immunoglobulin receptor, Myeloperoxidase, Peroxiredoxin-1, Protein S100-A11, Alpha-2-macroglobulin, Cystatin-C, Histone H2A, Histone H2B, Tubulin alpha-1B and Annexin A3.

An assay for testing a subject for diabetes or a predisposition to diabetes including analysing a biological fluid from a subject for the presence of one or more proteins selected from the group consisting of Alpha 2 macroglobulin, Apolipoprotein All, Immunoglobulin alpha heavy chain constant region, Immunoglobulin mu chain C region, Chain A of Human IgA1, Inter-alpha-trypsin inhibitor heavy chain H4 precursor, and Apolipoprotein B100; wherein detection of the protein is indicative of diabetes or a predisposition to diabetes in the subject

A composition for treating a nucleic acid duplex, wherein the composition is capable of inhibiting denaturation of the duplex, characterised in that the composition comprises a ubiquitin-like protein and / or a macroglobulin. It has been found that ubiquitin-like proteins (e.g. ubiquitin, NEDD8, RAD23, etc.) and macroglobulins (eg. α2-macroglobulin) are able to stabilise nucleic acid duplexes. A nucleic acid duplex which has been contacted with the composition of the invention can be subjected to more stringent processing conditions, with denaturation of the duplex being inhibited, than would otherwise be possible. Corresponding methods and uses are also provided.

Activation of .alpha..sub.2-macroglobulin (.alpha..sub.2M) with a nucleophilic compound followed by incubation of the activated .alpha..sub.2M at elevated temperature with a biomolecule results in covalent incorporation of the intact biomolecule into the .alpha..sub.2M molecule, without the use of proteinases. The thus-formed structurally defined and stable complex may be used as an antigen for stimulating the immune response, for example, in the form of a vaccine. Enhanced antigen presentation of a particular biomolecule is provided, especially for those that are poorly immunogenic; reduction of the immunodominance of particular epitopes is also provided.